ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Rocket releases positive results from Leukocyte Adhesion Deficiency-I trial
April 16, 2021Interim Phase I/II trial results show Rocket’s ex vivo lentiviral gene therapy candidate, RP-L201, is safe and of benefit to paediatric patients with severe Leukocyte Adhesion Deficiency-I. -
Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I)
November 26, 2018Rocket Pharmaceuticals, Inc., a leading U.S.-based multi-platform gene therapy company, today announces the clearance of the Company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for RP-L201.
Pharma Sources Insight January 2025
